Second interim analysis of Global Investigation of Therapeutic Decisions in Unresectable HCC and of its Treatment with Sorafenib (GIDEON): U.S. versus global perspective on patient and disease characteristics, treatment history, and sorafenib use.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: New York University, USC Norris Comprehensive Cancer Center, University of Louisville, University of California, San Francisco, Methodist Dallas Medical Center, Case Western Reserve University, University of Alabama at Birmingham, Virginia Commonwealth University, Johns Hopkins University, University of Michigan
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2271033429